- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00369850
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
Investigating Bone Density and Bone Loss Without Baseline Information
RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment.
PURPOSE: This phase III trial is studying bone density and bone loss in postmenopausal women with breast cancer receiving treatment in clinical trial IBCSG-1-98.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
- Compare the effects on bone mineral density (BMD) in the L2-L4 (posterio-anterior) region of the spine and hip by assessing bone density in postmenopausal women with breast cancer receiving treatment on protocol IBCSG-1-98.
- Compare the incidence of radiological gross changes and fractures identified from spine x-rays (T4-L4) in these patients (in groups 1 and 2).
- Use longitudinal BMD measurements to estimate a linear rate of bone loss based on mixed effect models.
- Identify serum markers for bone loss to determine how they correlate with osteoporosis, microfractures, clinical fractures, and breast cancer-related bone events.
OUTLINE: This is a multicenter study and a substudy of protocol IBCSG-1-98. Patients are assigned to 1 of 3 groups according to the length of treatment they have undergone on protocol IBCSG-1-98.
- Group 1 (prior to or at the end of the second year of treatment on protocol IBCSG-1-98): Patients undergo bone mineral density (BMD) testing of the L2-L4 spine and hip at baseline and years 1, 2, 3, and 4 from baseline. They also undergo x-rays of the T4-L4 spine at baseline and years 1, 3, and 4 from baseline.
- Group 2 (after 2 years but before the end of the third year of treatment on protocol IBCSG-1-98): Patients undergo BMD testing of the L2-L4 spine and hip at baseline and years 1, 2, and 3 from baseline. They also undergo x-rays of the T4-L4 spine at baseline and years 2 and 3 from baseline.
- Group 3 (after 3 years but before the end of the fifth year of treatment on protocol IBCSG-1-98): Patients undergo BMD testing of the L2-L4 spine and hip at baseline and years 1 and 2 from baseline (for patients in 4th year of treatment) or year 1 from baseline (for patients in 5th year of treatment).
Patients undergo blood collection at baseline and periodically during study for biomarker correlative study.
PROJECTED ACCRUAL: A total of 660 patients will be accrued for this study.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Institute of Oncology at Prince of Wales Hospital
-
-
Queensland
-
Brisbane, Queensland, Australien, 4029
- Royal Brisbane and Women's Hospital
-
-
-
-
-
Bordeaux, Frankreich, 33076
- Institut Bergonié
-
-
-
-
-
Aviano, Italien, 33081
- Centro di Riferimento Oncologico - Aviano
-
Bergamo, Italien, 24100
- Ospedali Riuniti di Bergamo
-
Milano, Italien, 20141
- European Institute of Oncology
-
-
-
-
-
Dunedin, Neuseeland
- Dunedin Hospital
-
-
-
-
-
Lima, Peru, 34
- Instituto Nacional de Enfermedades Neoplasicas
-
-
-
-
-
Aarau, Schweiz, CH-5001
- Kantonspital Aarau
-
Bern, Schweiz, CH-3010
- Inselspital Bern
-
Lausanne, Schweiz, CH-1011
- Centre Hospitalier Universitaire Vaudois
-
Mendrisio, Schweiz, CH-6850
- Ospedale Beata Vergine
-
St. Gallen, Schweiz, CH-9007
- Kantonsspital - St. Gallen
-
Thun, Schweiz, 3600
- Regionalspital
-
-
-
-
-
Madrid, Spanien, 28034
- Hospital Ruber Internacional
-
-
-
-
-
Cape Town, Südafrika, 7925
- Groote Schuur Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Diagnosis of breast cancer
- Resected disease
Enrolled on protocol IBCSG-1-98
Receiving adjuvant endocrine therapy comprising 1 of the following regimens:
- Letrozole
- Tamoxifen
- Letrozole after 2 years of tamoxifen
- Tamoxifen after 2 years of letrozole
- Not yet completed 5 years of treatment
- No breast cancer recurrence or second primary cancer
- No known, symptomatic bone disease, including osteomalacia or osteogenesis imperfecta
- No prior registration to protocol IBCSG-1-98 Bone Mineral Density substudy
Hormone receptor status:
- Estrogen receptor-positive and/or progesterone receptor-positive tumor
PATIENT CHARACTERISTICS:
- Female
- Postmenopausal
- No uncontrolled thyroid or parathyroid disease, Cushing's disease, or other pituitary diseases
- No malabsorption syndrome or clinically relevant vitamin D deficiency
- No patients for whom the bone density determination is impossible
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 1 year since prior and no concurrent anticonvulsants
- More than 6 weeks since prior and no concurrent corticosteroids (at doses > the equivalent of 5 mg/day prednisone) for > 2 weeks total
- No prior or concurrent sodium fluoride (at daily doses ≥ 5 mg/day) for > 1 month
- More than 12 months since prior and no concurrent anabolic steroids
- More than 6 months since prior treatment, either investigational or not, for the prevention of osteoporosis (excluding calcium or cholecalciferol [vitamin D])
- No concurrent raloxifene
- Concurrent therapeutic intervention for osteoporosis comprising bisphosphonates allowed
- Concurrent warfarin allowed provided it is given for ≤ 4 weeks
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Tamoxifen 2 Jahre plus Letrozol 3 Jahre
Patienten, die 2 Jahre lang mit Tamoxifen und anschließend 3 Jahre lang mit Letrozol behandelt wurden.
|
Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
|
Experimental: Tamoxifen for 5 years
Patients treated with tamoxifen for 5 years after randomisation.
|
Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
|
Experimental: Letrozole for 5 years
Patients treated with letrozole for 5 years after randomisation.
|
Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
|
Experimental: Letrozole 2 years plus tamoxifen 3 years
Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
|
Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Relative percent change of bone mineral density (BMD) form baseline to after 2, 3, 4, or 5 years of treatment on protocol IBCSG-1-98
Zeitfenster: 5 years after randomisation to BIG 1-98
|
5 years after randomisation to BIG 1-98
|
Recovery of BMD at 1 year after the completion of treatment on protocol IBCSG-1-98
Zeitfenster: 6 years after randomisation to BIG 1-98
|
6 years after randomisation to BIG 1-98
|
Proportion of patients with BMD below the absolute threshold value for osteoporosis
Zeitfenster: 5 years after randomisation to BIG 1-98
|
5 years after randomisation to BIG 1-98
|
Relative percent change in markers of bone resorption from baseline to after 2, 3, 4, or 5 years of treatment on protocol IBCSG-1-98
Zeitfenster: 5 years after randomisation to BIG 1-98
|
5 years after randomisation to BIG 1-98
|
Recovery of the markers of bone resorption at 1 year after the completion of treatment on protocol IBCSG-1-98
Zeitfenster: 6 years after randomisation to BIG 1-98
|
6 years after randomisation to BIG 1-98
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienstuhl: Stefan Aebi, MD, University Hospital Inselspital, Berne
- Studienstuhl: Andrea Decensi, MD, European Institute of Oncology
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CDR0000482381
- NOVARTIS-2026703019 (Andere Kennung: Novartis)
- IBCSG-18-98-BS (Andere Kennung: IBCSG)
- EU-20623 (Andere Kennung: EU)
- IBCSG-1-98-BS (Andere Kennung: IBCSG)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten
Klinische Studien zur laboratory biomarker analysis
-
Vanderbilt University Medical Center4DMedicalAbgeschlossen
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Noch keine RekrutierungHIV-Infektionen | Hepatitis B
-
Duke UniversityZurückgezogenAntikoagulations- und Thrombose-Point-of-Care-Test (AT-POCT)Vereinigte Staaten
-
Columbia UniversityAbgeschlossen
-
McGill University Health Centre/Research Institute...Northwestern UniversityRekrutierungApnoe der FrühgeburtlichkeitKanada
-
Emory UniversityDermatology FoundationBeendetKutaner Lupus erythematodesVereinigte Staaten